Showing 38,141 - 38,160 results of 104,039 for search '(( 19 mean decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.69s Refine Results
  1. 38141

    A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors by Menghao Li (727830)

    Published 2022
    “…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
  2. 38142

    Calorie restriction leads to telomere maintenance and/or elongation with time in a percentage of mice. by Elsa Vera (93180)

    Published 2013
    “…<p>(A, C and E) The behavior of mean telomere length was classified in two different profiles (“Decrease” and “Increase or Maintenance”) at different times of diet (1–22 months of diet, 5–22 months of diet and 9–22 months of diet; A, C and E, respectively) in the indicated groups. …”
  3. 38143
  4. 38144
  5. 38145
  6. 38146

    Treatment of 2D cell culture by a γ-secretase inhibitor. by Han-Kyu Lee (3184848)

    Published 2016
    “…B. Aβ42 levels were significantly decreased in all 5 AD subjects after treatment with the γ-secretase inhibitor at all doses tested. …”
  7. 38147

    A large proportion of NSCs redivide within 24 to 72 h. by Valerio Lupperger (9745714)

    Published 2020
    “…(B–E) Example DLS (yellow arrow) for a labeling interval Δt = 9 h. (F) The DLS proportion is high for Δt = 9 h and decreases rapidly with increasing Δt. …”
  8. 38148
  9. 38149

    Baseline characteristics. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  10. 38150

    Subgroup analyses for the primary outcome. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  11. 38151

    Outcomes. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  12. 38152

    Trial profile. by Nattapat Nitinai (17896679)

    Published 2024
    “…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
  13. 38153

    Utilizing reduction in spheroid counts and/or total nuclear intensity to determine toxic effects of compounds. by Pranjali Beri (14945400)

    Published 2023
    “…They are indicated appropriately in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0287809#pone.0287809.g004" target="_blank">Fig 4</a>. …”
  14. 38154
  15. 38155

    Synthesis of a Dialuminum-Substituted Silicotungstate and the Diastereoselective Cyclization of Citronellal Derivatives by Yuji Kikukawa (1929586)

    Published 2008
    “…The reaction of <b>1</b> with pyridine yielded TBA<sub>3</sub>[(C<sub>5</sub>H<sub>5</sub>N)H][γ-SiW<sub>10</sub>O<sub>36</sub>{Al(C<sub>5</sub>H<sub>5</sub>N)}<sub>2</sub>(μ-OH)<sub>2</sub>]·2H<sub>2</sub>O (<b>2</b>), and the molecular structure was successfully determined by the X-ray crystallographic analysis. …”
  16. 38156

    Synthesis of a Dialuminum-Substituted Silicotungstate and the Diastereoselective Cyclization of Citronellal Derivatives by Yuji Kikukawa (1929586)

    Published 2008
    “…The reaction of <b>1</b> with pyridine yielded TBA<sub>3</sub>[(C<sub>5</sub>H<sub>5</sub>N)H][γ-SiW<sub>10</sub>O<sub>36</sub>{Al(C<sub>5</sub>H<sub>5</sub>N)}<sub>2</sub>(μ-OH)<sub>2</sub>]·2H<sub>2</sub>O (<b>2</b>), and the molecular structure was successfully determined by the X-ray crystallographic analysis. …”
  17. 38157

    GGA3 deletion induces a reduction in anxiety-like behaviors. by Kendall R. Walker (2794000)

    Published 2016
    “…<p>GGA3 null mice display decreased anxiety-like behaviors in two different testing paradigms (A-C: Elevated Plus Maze; D-F: Light-Dark Transition). …”
  18. 38158

    Comorbidity and progression of late onset Alzheimer’s disease: A systematic review by Miriam L. Haaksma (4003163)

    Published 2017
    “…<div><p>Background</p><p>Alzheimer’s disease is a neurodegenerative syndrome characterized by multiple dimensions including cognitive decline, decreased daily functioning and psychiatric symptoms. …”
  19. 38159
  20. 38160

    Supplement information is provided in a separate file named “S1 File”. by Simone Gorressen (605474)

    Published 2015
    “…<p><b>Table A—BC−/EC+ exhibited decreased ejection fraction and increased end-systolic and end-diastolic volumes (Table A is included in the “S1 File”).…”